ENLV

Healthcare Biotechnology

Enlivex Ltd.

$0.30

-0.04 -12.74% today Live

Price History

Not enough data

Price chart data
Date	Price
Oct 7, 2026, live at 1:56 PM ET	0.30

Key Stats

Market Cap

5.98M

Avg Volume

376,696

P/E (TTM)

0.00

EPS

$494.00

52W High

$27.15

52W Low

$0.30

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-0.39

P/B Ratio

0.00

EV/EBITDA

-0.74

Margins

Gross Margin 0.0%

Operating Margin 0.0%

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Equity

162.9%

Return on Assets

(0.6%)

Liquidity & Leverage

Current Ratio

119.39

Quick Ratio

0.18

Debt / Equity

0.00

Total Cash

5.52M

Total Debt

17.54M

About

Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2. Enlivex Ltd. was formerly known as Enlivex Therapeutics Ltd. and changed its name to Enlivex Ltd. in February 2026. The company was founded in 2005 and is headquartered in Ness Ziona, Israel.